Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2017 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Third Quarter 2017 Financial Results and Business Updates

– GlaxoSmithKline plc (LSE/NYSE:GSK) exercised its option to license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program –– Adaptimmune will receive up...
October 27, 2017 11:11 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report Third Quarter 2017 Financial Results on November 2, 2017

PHILADELPHIA and OXFORD, U.K., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the...
October 23, 2017 17:51 ET | Source: Adaptimmune Therapeutics plc

Sébastien Desprez Joins Adaptimmune as Vice President of Communications and Investor Relations

PHILADELPHIA and OXFORD, U.K., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Sébastien Desprez has...
September 22, 2017 09:59 ET | Source: Adaptimmune Therapeutics plc

James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

PHILADELPHIA and OXFORD, U.K., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble,...
September 07, 2017 07:30 ET | Source: Adaptimmune Therapeutics plc

GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that...
August 30, 2017 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker

PHILADELPHIA and OXFORD, U.K., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its...
August 03, 2017 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Second Quarter 2017 Financial Results

– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 – – Enrolling 9 clinical studies...
July 31, 2017 16:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017

PHILADELPHIA and OXFORD, United Kingdom, July 31, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for...
June 05, 2017 09:50 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting

PHILADELPHIA and OXFORD, United Kingdom, June 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral...
May 26, 2017 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting

PHILADELPHIA and OXFORD, United Kingdom, May 26, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral...